

Contact

T +49 (0)211 301 257 0

F +49 (0)211 301 257 11

E Grabow@maiwald.eu



Dr. Gisela Grabow

Counsel

Lawyer (England/Wales)

Gisela is particularly active in international legal issues involving contractual, cross-border, regulatory and EU matters in the pharmaceutical, biotech, foodstuff, medical devices and automotive sectors.

She has over ten years of experience in negotiations of (international) agreements, from development collaborations to patent portfolio sales, manufacturing, marketing authorisation to distribution and large scale licensing.

She studied law at universities in England, Germany and Den Haag. After her studies, she worked as a legal trainee for law firms in Germany and London, and then as a temporary Lawyer (foreign services) in Texas, USA and at an international organisation. Gisela specialised, inter alia, in international and European commercial law, including IP law, and international and European law on dispute resolution (settlement of cross-border disputes) during her graduate and postgraduate studies LL.M.) as well as for her PhD.

Gisela also worked in Legal Consultant positions at an international organisation. As president of a European legal commission, she regularly publishes comments on legislative proposals of the EU Commission and monitors changes in EU law.

CAREER

since 2022	Counsel at Maiwald
2019 - 2022	Principal at Maiwald
2015 - 2019	Senior Associate at Maiwald
2011 - 2015	Associate at Maiwald
2008 - 2011	Legal traineeship and legal consultant positions at an international organisation

EDUCATION

2016	Doctoral studies (Dr. iur.) in Germany and England
2009 - 2011	Legal traineeship and Temporary Lawyer (Foreign Services) in Texas

PRACTICE AREAS

- Pharmaceutical Law
- Compliance
- Trademarks & Designs
- Competition & Antitrust Law
- Agreements

SERVICES

- Negotiation and drafting of international contracts
- EU regulatory affairs (pharma, medical devices, biotech and food)
- Support in cross-border cartel and competition law proceedings

PUBLICATIONS

- Ergänzende Schutzzertifikate für Arzneimittel, EuZW 2023, 643
- A path towards a crisis-proof EU pharmaceutical legislation? The European Commission proposal, MIP 2023
- Quo vadis Arzneimittelrecht – ein Überblick zur Überarbeitung der EU-Arzneimittelvorschriften, PharmR 6/2023
- Ergänzende Schutzzertifikate – Überblick und Ausblick zur EU-Initiative, Arzneimittel & Recht, 2022
- EU-Initiative zu Zwangslizenzen – Chance oder Wettbewerbsnachteil? Arzneimittel & Recht, 2022
- Alignment of Pharmaceutical Strategy for Europe with the Action Plan on IP, 2021
- EMA and EU Commission offer flexibility instead of intervention, 2020
- Proposed Regulation Increasing Transparency at the EFSA Threatens IP, 2019
- EU Commission Consultation on „Measures on animal cloning for food production in the EU“, Regulation No. 258/97 concerning novel foods and novel food ingredients
- EU Commission Consultation on ‘Genetically modified crops’
- EU Commission Consultation on a possible extension of geographical indication protection of the European Union to non-agricultural products which is named “Making the most out of Europe’s traditional know-how”
- „A review of the EU regime for the fruit and vegetables sector – public consultation on policy options and their impact assessment“
- EU Commission consultation on “Evaluation of the activities of the EU Intellectual Property Office related to enforcement and the European Observatory on Infringements of Intellectual Property Rights (Regulation No 386/2012)”
- EU Consultation on the Report and Analysis of the Application of Directive 2004/48/EC

LANGUAGES

- German and English (bilingual)
- French